From: Screening for IgG4-type anti-nuclear antibodies in IgG4-related disease
Case | Age | IgG4a | IgGa | ANA Specific Abs | RFb | Clinical manifestations | Biopsy source, IgG4+/IgG+ cell ratio |
---|---|---|---|---|---|---|---|
1 | 73 | 2890 | 3668 | 40 (Homo + Spe) | <6 | Mikulicz’s disease, Prostatitis, LN | Prostate, 0.60 |
2 | 76 | 2210 | 3632 | 40 (Spe) | <6 | Mikulicz’s disease, RPF | Submandibular gl, 0.40 |
3c | 79 | 1460 | 3669 | 160 (Homo + Spe) Anti-SS-A+ | <6 | Küttner’s tumor, IP, IN, RPF, LN | Submandibular gl, 0.73 |
4 | 66 | 1090 | 2301 | 40 (Homo + Spe) | 30.3 | AIP, IN, Renal pseudotumor | Kidney, 0.70 |
5c | 73 | 592 | 3321 | 320 (Homo + Spe) | <6 | Sialadenitis, IP, IN, RPF, LN | Submandibular gl, 0.43 |
6 | 74 | 389 | 2184 | <40 | <6 | Retroorbital tumor | Retroorbital tumor, 0.48 |
7 | 52 | 383 | 1748 | <40 | <6 | Küttner’s tumor | Submandibular gl, 0.57 |
8 | 70 | 724 | 1729 | <40 | <6 | Küttner’s tumor, LN | Submandibular gl, 0.40 |
9 | 46 | 675 | 1617 | 80 (Homo + Spe) | 26.8 | Mikulicz’s disease | Lachrymal gl, 0.41 |
10 | 37 | 533 | 1741 | <40 | <6 | Mikulicz’s disease | Lachrymal gl, 0.50 |
11 | 76 | 458 | 1527 | <40 | <6 | AIP, RPF | Retroperitoneal tumor, 0.70 |
12 | 62 | 315 | 1809 | 40 (Spe) Anti-SS-A+ | <6 | AIP, RPF | Pancreas, 0.43 |
13 | 79 | 1960 | 2953 | 40 (Homo + Spe) | 65 | Orbital tumor, Lung nodule, LN | Orbital tumor, 0.59 |
14c | 62 | 1460 | 2177 | 40 (Spe) | 23.3 | Sialadenitis, Laryngeal tumor, LN | Parotid gl, 0.60 Cervical LN, 0.69 |
15 | 65 | 1050 | 1811 | <40 | 19.8 | Mikulicz’s disease, LN | Submandibular LN, 0.80 |
16 | 25 | 1210 | 2181 | <40 | <6 | Mikulicz’s disease, IP, IN, Renal pseudotumor, LN | Minor salivary gl, 0.65 |
17 | 55 | 1510 | 3116 | <40 | 72.2 | Orbital tumor, RPF, Lung nodule, LN | Cervical LN, 0.90 |
18 | 61 | 491 | 1466 | 80 (Spe + Granular) | <6 | Sialadenitis | Submandibular gl, 0.48 |
19 | 78 | 1470 | 3762 | 80 (Homo + Spe) | 35 | AIP, RPF | Vater’s ampulla, 0.48 |